- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
834
Companies which are more than 50% undervalued based on analyst price target.
834 companies
Bio-Path Holdings
Market Cap: US$1.4m
Operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
BPTH
US$0.16
7D
8.7%
1Y
-94.0%
Aptevo Therapeutics
Market Cap: US$1.2m
A clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
APVO
US$0.34
7D
-32.1%
1Y
-99.0%
GRI Bio
Market Cap: US$840.6k
A clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
GRI
US$1.47
7D
-30.0%
1Y
-98.4%
cbdMD
Market Cap: US$673.3k
Produces and distributes various cannabidiol (CBD) products in the United States.
YCBD
US$0.94
7D
-37.8%
1Y
-82.7%
Scandion Oncology
Market Cap: SEK 4.4m
A clinical-stage biotechnology company, develops medicines for the treatment of cancer.
SCOL
SEK 0.019
7D
46.9%
1Y
-98.6%
Altamira Therapeutics
Market Cap: US$400.1k
Operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe.
CYTO.F
US$0.077
7D
-22.8%
1Y
-94.7%